NICE endorses liquid-based cytology
This article was originally published in The Gray Sheet
Executive Summary
National Institute for Clinical Excellence final appraisal determination issued Aug. 15 recommends using the technology as the primary means of processing samples in the UK's cervical screening program. Implementation of the policy - representing 4 mil. annual tests - should take about three to five years. The decision was applauded by LBC stakeholders Cytyc (ThinPrep) and TriPath (SurePath). NICE issued a preliminary recommendation in April (1"The Gray Sheet" April 21, 2003, p. 6)...
You may also be interested in...
Liquid-based cytology
Technology is recommended by NICE in 1LBC guidance as the primary means of processing Pap smear samples in the UK's cervical screening program. The UK body released a final appraisal on the procedure in August (2"The Gray Sheet" Aug. 18, 2003, In Brief)...
Liquid-Based Cytology Recommended For UK By NICE Appraisal Committee
A preliminary recommendation in favor of liquid-based cytology (LBC) adoption in the UK reverses a June 2000 National Institute for Clinical Excellence (NICE) guidance which concluded that data were insufficient to support nationwide use
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.